DE69432861D1 - Verfahren zur Bewertung von chemotherapeutischen Mitteln in vivo - Google Patents

Verfahren zur Bewertung von chemotherapeutischen Mitteln in vivo

Info

Publication number
DE69432861D1
DE69432861D1 DE69432861T DE69432861T DE69432861D1 DE 69432861 D1 DE69432861 D1 DE 69432861D1 DE 69432861 T DE69432861 T DE 69432861T DE 69432861 T DE69432861 T DE 69432861T DE 69432861 D1 DE69432861 D1 DE 69432861D1
Authority
DE
Germany
Prior art keywords
vivo
chemotherapeutic agents
evaluating
test agent
laboratory animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432861T
Other languages
English (en)
Other versions
DE69432861T2 (de
Inventor
Melinda Hollingshead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69432861D1 publication Critical patent/DE69432861D1/de
Application granted granted Critical
Publication of DE69432861T2 publication Critical patent/DE69432861T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69432861T 1993-05-05 1994-04-21 Verfahren zur Bewertung von chemotherapeutischen Mitteln in vivo Expired - Lifetime DE69432861T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58154 1993-05-05
US08/058,154 US5698413A (en) 1993-05-05 1993-05-05 Method of evaluating chemotherapeutic agents in vivo
PCT/US1994/004443 WO1994025074A1 (en) 1993-05-05 1994-04-21 Method of evaluating chemotherapeutic agents in vivo

Publications (2)

Publication Number Publication Date
DE69432861D1 true DE69432861D1 (de) 2003-07-31
DE69432861T2 DE69432861T2 (de) 2004-05-19

Family

ID=22015035

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432861T Expired - Lifetime DE69432861T2 (de) 1993-05-05 1994-04-21 Verfahren zur Bewertung von chemotherapeutischen Mitteln in vivo

Country Status (8)

Country Link
US (1) US5698413A (de)
EP (1) EP0697892B1 (de)
JP (1) JPH08512292A (de)
AT (1) ATE243532T1 (de)
AU (1) AU697146B2 (de)
CA (1) CA2162165C (de)
DE (1) DE69432861T2 (de)
WO (1) WO1994025074A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042909A (en) * 1997-09-03 2000-03-28 Circe Biomedical, Inc. Encapsulation device
US6022733A (en) * 1997-12-02 2000-02-08 Tam; Yun K. Simulated biological dissolution and absorption system
DE50006599D1 (de) 1999-03-09 2004-07-01 Acordis Ind Fibers Gmbh Membranmodul zum testen von wirkstoffen an zellen
US6616912B2 (en) 2001-01-05 2003-09-09 Spectrum Laboratories, Inc. Bi-component microporous hollow fiber membrane structure for in vivo propagation of cells
EP1364206A2 (de) * 2001-01-09 2003-11-26 Novartis AG Schnelles screening-verfahren für in vivo wirksame verbindungen
WO2003046139A2 (en) * 2001-11-26 2003-06-05 Exelixis, Inc. CRBs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHOD OF USE
US20040045045A1 (en) * 2002-05-30 2004-03-04 Mather Jennie P. Animal model for toxicology and dose prediction
EP1656447A2 (de) * 2003-05-29 2006-05-17 AstraZeneca AB Testen des zellzyklusregulationseffekts einer verbindung unter verwendung eines hohlfaser-zellimplantats
MX2010000918A (es) * 2007-07-24 2010-03-15 Astellas Pharma Inc Derivado de bencimidazol.
WO2009023185A1 (en) 2007-08-13 2009-02-19 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
JP2010540534A (ja) * 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
RU2573912C2 (ru) 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
JPWO2010087319A1 (ja) * 2009-01-27 2012-08-02 アステラス製薬株式会社 前立腺癌治療剤として有効な物質のスクリーニング方法
JP6895674B2 (ja) * 2015-10-21 2021-06-30 国立大学法人 東京大学 マイクロチューブ、マイクロチューブの製造方法、及びマイクロチューブの製造装置
CN107976534A (zh) * 2016-10-21 2018-05-01 上海立迪生物技术股份有限公司 一种抗肿瘤药物快速药效筛选方法及其专用装置
EP4161653A1 (de) 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
CN116917326A (zh) 2021-01-22 2023-10-20 博泰康医药公司 抗her-2/trop-2构建体及其用途
CN117660581A (zh) * 2022-09-01 2024-03-08 上海立迪生物技术股份有限公司 一种筛选免疫调节药物药效的模型及方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759911A (fr) * 1969-12-05 1971-05-17 Worthington Biochem Corp Produits enzymatiques actifs
US4324683A (en) * 1975-08-20 1982-04-13 Damon Corporation Encapsulation of labile biological material
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4409331A (en) * 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4495288A (en) * 1981-03-13 1985-01-22 Damon Biotech, Inc. Method of culturing anchorage dependent cells
CA1265443A (en) * 1985-09-18 1990-02-06 Elieser Gorelik Assays for chemotherapeutic agents
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5416022A (en) * 1988-08-10 1995-05-16 Cellex Biosciences, Inc. Cell culture apparatus
WO1991015245A1 (en) * 1990-03-30 1991-10-17 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE Method and composition for growing tumors from few cells
JP3252361B2 (ja) * 1991-10-02 2002-02-04 ミルトン・エイチ・リプスキー インビボにおける癌の治療のアッセイ

Also Published As

Publication number Publication date
AU6711594A (en) 1994-11-21
EP0697892A1 (de) 1996-02-28
CA2162165A1 (en) 1994-11-10
WO1994025074A1 (en) 1994-11-10
ATE243532T1 (de) 2003-07-15
US5698413A (en) 1997-12-16
AU697146B2 (en) 1998-10-01
JPH08512292A (ja) 1996-12-24
DE69432861T2 (de) 2004-05-19
EP0697892B1 (de) 2003-06-25
CA2162165C (en) 2008-07-08

Similar Documents

Publication Publication Date Title
DE69432861D1 (de) Verfahren zur Bewertung von chemotherapeutischen Mitteln in vivo
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
DE69816272D1 (de) Cyanidfreie lytische reagenzzusammensetzung und verfahren zur hämoglobin- und zellanalyse
DE3853254T2 (de) Ausrüstungssatz und Verfahren für Analysen von biologischen Proben.
DE60235464D1 (de) Knochenmarkersatzmaterial-verbundwerkstoff, verfahren zu seiner herstelllung und kit
DE3778355D1 (de) Verfahren zur entkeimung von mit lebenden zellen umgebenen oberflaechen.
NO20004451L (no) FremgangsmÕte for Õ utføre telling av blodceller
DE3752020D1 (de) Spektrometerobjektiv für Korpuskularstrahlmessgeräte und Verfahren zur Untersuchung von Proben.
DE69026024D1 (de) Künstlicher Träger zur Immobilisierung von biologischen Proteinen und Verfahren zu seiner Herstellung
DE3686414D1 (de) Verfahren zur bewertung von restermuedungsdauer mechanischer teile.
ATE414417T1 (de) Translations-kontrollelemente für proteinexpression mit hoher ausbeute in den plastiden von höheren pflanzen und verfahren zu deren verwendung
HK1024413A1 (en) Liver function test
DE3885733D1 (de) Verfahren zur befreiung von zellgemischen und geweben von unerwünschten populationen.
ATE222122T1 (de) Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen
DE3678621D1 (de) Verfahren und testzusammensetzung zur bestimmung von wasserstoffperoxyd.
DE69007934D1 (de) Verankerung für Spannglied und Verfahren zu seiner Herstellung.
DE69603174T2 (de) Verfahren zur mikrobiologischen dekontaminierung von blutplättchen
ATE333508T1 (de) Verfahren in vitro zum einbringen von nukleinsäure in eine zelle (transfektion) mittels calciumphosphat
DE69016249D1 (de) Verfahren zur elektrochemischen Behandlung von Schwefelwasserstoff enthaltendem Gas.
DE69918132D1 (de) Verfahren zur erkennung und messung von gespleisten nukleinsäuren
DE69609586T2 (de) Verfahren zur Bewertung von Substanzen zum Steigen bzw. zur Modifizierung der APC-Aktivität
DE69618630T2 (de) Methode zur in vitro-bestimmung der bioaktivität von erythropoietin
ATA141089A (de) Verfahren zur einmischung von wasserstoffperoxidloesung
ATE18071T1 (de) Verfahren zur vorbereitung von alloplastischen implantationen und organtransplantationen.
DE406296T1 (de) Verfahren zur sequenzanalyse von dna.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition